Since the launch of its drug Mounjaro last year, it's clear that Eli Lilly (NYSE: LLY) has become a strong competitor to Novo Nordisk (NYSE: NVO) and its early dominance in the market for medicines that treat obesity and type 2 diabetes.

And now, Eli Lilly could have a further trick up its sleeve. While Novo Nordisk's portfolio includes household names like Ozempic, Rybelsus, and Wegovy, Eli Lilly's retatrutide -- currently in clinical trials -- might be an even bigger winner.

So does that make Eli Lilly's stock worth buying today? Let's dive in and see what's going on.

Continue reading

Source Fool.com